DK2158331T3 - Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler - Google Patents

Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler

Info

Publication number
DK2158331T3
DK2158331T3 DK08759217T DK08759217T DK2158331T3 DK 2158331 T3 DK2158331 T3 DK 2158331T3 DK 08759217 T DK08759217 T DK 08759217T DK 08759217 T DK08759217 T DK 08759217T DK 2158331 T3 DK2158331 T3 DK 2158331T3
Authority
DK
Denmark
Prior art keywords
abcb1
drugs
lack
context
clinical response
Prior art date
Application number
DK08759217T
Other languages
English (en)
Inventor
Florian Holsboer
Manfred Uhr
Bertram Mueller-Myhsok
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK2158331T3 publication Critical patent/DK2158331T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK08759217T 2007-06-12 2008-06-12 Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler DK2158331T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94333507P 2007-06-12 2007-06-12
PCT/EP2008/004737 WO2008151803A2 (en) 2007-06-12 2008-06-12 New polymorphisms in abcb1 associated with a lack of clinical response to medicaments

Publications (1)

Publication Number Publication Date
DK2158331T3 true DK2158331T3 (da) 2012-12-17

Family

ID=39735268

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08759217T DK2158331T3 (da) 2007-06-12 2008-06-12 Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler
DK12179060T DK2520670T3 (da) 2007-06-12 2008-06-12 Nye polymorphier i ABCB1 forbundet med en mangel på klinisk respons over for lægemidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12179060T DK2520670T3 (da) 2007-06-12 2008-06-12 Nye polymorphier i ABCB1 forbundet med en mangel på klinisk respons over for lægemidler

Country Status (6)

Country Link
US (2) US9115398B2 (da)
EP (2) EP2158331B1 (da)
DK (2) DK2158331T3 (da)
ES (2) ES2394529T3 (da)
PL (2) PL2158331T3 (da)
WO (1) WO2008151803A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
CA2821547A1 (en) 2010-12-29 2012-07-05 Sigma-Aldrich Co. Llc Cells having disrupted expression of proteins involved in adme and toxicology processes
WO2012103060A1 (en) * 2011-01-27 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
CN102912003A (zh) * 2011-08-02 2013-02-06 广州益善生物技术有限公司 一种abcb1基因多态性检测特异性引物和液相芯片
GB201210686D0 (en) * 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
US11694539B2 (en) * 2020-06-16 2023-07-04 Heartware, Inc. Notification system for low-level preventative LVAD alerts
CN113584160A (zh) * 2021-06-15 2021-11-02 湖南菲思特精准医疗科技有限公司 一种昂司丹琼代谢标志物检测试剂盒及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697207A1 (en) 1999-07-30 2001-02-08 Epidauros Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
WO2005108605A2 (en) 2004-05-12 2005-11-17 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Polymorphisms in abcb1 associated with a lack of clinical response to medicaments

Also Published As

Publication number Publication date
US20100184742A1 (en) 2010-07-22
US20160067262A1 (en) 2016-03-10
ES2456919T3 (es) 2014-04-24
DK2520670T3 (da) 2014-05-26
ES2394529T3 (es) 2013-02-01
EP2158331A2 (en) 2010-03-03
PL2520670T3 (pl) 2014-07-31
US9901582B2 (en) 2018-02-27
WO2008151803A2 (en) 2008-12-18
WO2008151803A3 (en) 2009-02-26
PL2158331T3 (pl) 2013-01-31
EP2158331B1 (en) 2012-08-29
US9115398B2 (en) 2015-08-25
EP2520670B1 (en) 2014-02-26
EP2520670A1 (en) 2012-11-07

Similar Documents

Publication Publication Date Title
DK2520670T3 (da) Nye polymorphier i ABCB1 forbundet med en mangel på klinisk respons over for lægemidler
CY2020008I2 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
MA30236B1 (fr) Nouvelle composition pharmaceutique
DK3470077T3 (da) Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
ATE553084T1 (de) Polycyclische säureverbindungen als crth2- antagonisten und antiallergika
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
DK2442790T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser
DK2421879T3 (da) Nye 7-deazapurinnukleotider til terapeutiske anvendelser
EP2323515A4 (en) CONTAINER HOLDER WITH FIXING AGENTS
IL215467A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
EP2301525A4 (en) TOPICAL IBUPROFEN FORMULATION
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
EP2627427A4 (en) THINNING / DETERGENT CHEST WITH SPIRAL PERIPHERALS
EP2069541A4 (en) POLYMORPHISMS IN GENES WITH INFLUENCE ON DISEASES OF THE CENTRAL NERVOUS SYSTEM AND ITS APPLICATIONS
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
EP2394648A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
FR2933987B1 (fr) Procede d'hydrogenation du benzene
DE06722936T8 (de) Isomerisation pharmazeutischer zwischenprodukte
ATE512137T1 (de) Benzoylpiperidinderivate als doppelmodulatoren des 5-ht2a- und des d3-rezeptors
EP2465512A4 (en) PAIN-SUBJECTIVE PHARMACEUTICAL COMPOSITION
EP2411542A4 (en) POLYMORPHISM IN THE CYP3A4 GENE WITH EFFECT ON THE ACTIVE METABOLISM AND ITS USE
BRPI1010256A2 (pt) "aplicações terapêuticas no domínio cardiovascular de derivados de quinazolina diona."